Ocean Biomedical, Inc. (OCEA)
NASDAQ: OCEA · Real-Time Price · USD
0.0549
+0.0009 (1.67%)
At close: Apr 1, 2025, 4:00 PM
0.0499
-0.0050 (-9.16%)
After-hours: Apr 1, 2025, 4:55 PM EDT
Ocean Biomedical Employees
Ocean Biomedical had 9 employees as of December 31, 2021. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$2,957,667
Market Cap
7.26M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2021 | 9 | 1 | 12.50% |
Dec 31, 2020 | 8 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
OCEA News
- 7 weeks ago - Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development - GlobeNewsWire
- 2 months ago - Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway - GlobeNewsWire
- 4 months ago - Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - GlobeNewsWire
- 5 months ago - Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter - GlobeNewsWire
- 6 months ago - Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. - GlobeNewsWire
- 6 months ago - Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses - GlobeNewsWire
- 7 months ago - Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms - GlobeNewsWire
- 10 months ago - Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - GlobeNewsWire